跳至主要内容
临床试验/IRCT2014041417261N1
IRCT2014041417261N1已完成未知

Double blind randomized clinical trial of the Farantan (Bosentan) 125 mg on pulmonary arterial hypertension cases; a product of Faran pharmaceutical Company

Faran Pharmaceutical Company0 个研究点目标入组 30 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • The cases of pulmonary arterial hypertension (PAH), secondary to cardiac or connective tissue disorders (e.g. scleroderma, Eisenmenger's syndrome, etc.), which are in functional class II or higher (Due to drug deficiency and national guideline, Traclleer has not been prescribed for these patients, so far);
  • No finding of anemia, liver disorders, pregnancy and lactation, body fluid retention, peripheral or pulmonary edema and respiratory system infections;
  • No prescription of interactive medicines like Cyclosporine A and Glyburide;
  • Having voluntarily willingness for participation in the study;
  • Drug intolerance due to any reason;
  • Any severe or relatively severe side effects like increasing liver function tests (more than 3 times of baseline or 2 times of normal), anemia, severe pulmonary infection, fluid retention and edema, etc.;
  • Discontinuing of participation by the participants;
  • Irregular intake of Farantan due to any reason;
  • Any undesirable medical condition which urge the physicians to change the treatment.

排除标准

  • 未提供

研究者

发起方
Faran Pharmaceutical Company

相似试验